HomeAI · summaries
Storia in 5 fonti
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark…
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- ·
benzinga.com
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
